(Reuters) -Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce the symptoms of difficult-to-treat depression in a late-stage study.
The study, involving patients with treatment-resistant depression who did not respond to at least two types of antidepressants, opens a potential avenue for treating a condition that is notoriously difficult to manage.
The company said a 25 milligram dose of COMP360, combined with psychological support, enabled patients to achieve statistically significant reductions in depressive symptoms or remission.
This was measured on a standardized depression scale after six weeks of treatment, compared with a placebo.
Shares of Compass fell 24% to $3.50 in premarket trade.
(Reporting by Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Mrigank Dhaniwala and Anil D’Silva)
Comments